J&J/Veridex’ CellSearch System Paves Way For FDA Class II Designation
This article was originally published in The Gray Sheet
Executive Summary
FDA formally classifies immunomagnetic circulating cancer cell selection and enumeration systems as Class II with special controls in a May 11 final rule
You may also be interested in...
Immunicon IPO Proceeds To Support FDA Clearance Of Cancer Diagnostics
Johnson & Johnson/Veridex will stand to benefit from Immunicon's proposed $70.9 mil. IPO under the terms of the companies' exclusive development, licensing and marketing agreement for cancer diagnostics
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.